Equities research analysts forecast that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce earnings per share (EPS) of ($1.09) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for G1 Therapeutics’ earnings. The lowest EPS estimate is ($1.28) and the highest is ($0.98). G1 Therapeutics posted earnings of ($0.82) per share in the same quarter last year, which would suggest a negative year over year growth rate of 32.9%. The firm is expected to report its next earnings report on Wednesday, May 5th.
According to Zacks, analysts expect that G1 Therapeutics will report full-year earnings of ($4.21) per share for the current year, with EPS estimates ranging from ($5.03) to ($3.56). For the next financial year, analysts forecast that the firm will report earnings of ($3.41) per share, with EPS estimates ranging from ($4.11) to ($2.62). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, February 24th. The company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.21. The business had revenue of $16.55 million for the quarter, compared to the consensus estimate of $14.00 million.
In other G1 Therapeutics news, Director Mark A. Velleca sold 10,000 shares of G1 Therapeutics stock in a transaction that occurred on Wednesday, January 20th. The shares were sold at an average price of $21.51, for a total value of $215,100.00. Following the transaction, the director now owns 47,000 shares in the company, valued at $1,010,970. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Rajesh Malik sold 15,000 shares of G1 Therapeutics stock in a transaction that occurred on Tuesday, March 23rd. The stock was sold at an average price of $21.94, for a total transaction of $329,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,040 shares of company stock worth $1,502,608. 14.49% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in G1 Therapeutics by 222.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,378 shares of the company’s stock worth $25,000 after purchasing an additional 950 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in G1 Therapeutics during the 3rd quarter worth approximately $25,000. Pacer Advisors Inc. grew its position in G1 Therapeutics by 211.1% during the 4th quarter. Pacer Advisors Inc. now owns 4,076 shares of the company’s stock worth $73,000 after purchasing an additional 2,766 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in G1 Therapeutics by 80.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,118 shares of the company’s stock worth $92,000 after purchasing an additional 2,278 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in G1 Therapeutics during the 3rd quarter worth approximately $75,000. Hedge funds and other institutional investors own 77.89% of the company’s stock.
Shares of NASDAQ GTHX traded up $0.41 during mid-day trading on Friday, reaching $25.45. 22,013 shares of the company traded hands, compared to its average volume of 1,601,808. G1 Therapeutics has a fifty-two week low of $10.81 and a fifty-two week high of $37.07. The company has a debt-to-equity ratio of 0.10, a current ratio of 7.45 and a quick ratio of 7.45. The firm has a market cap of $1.07 billion, a PE ratio of -8.63 and a beta of 2.44. The stock has a fifty day simple moving average of $23.26 and a 200-day simple moving average of $18.77.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
Recommended Story: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.